CA2366884A1 - Administration amelioree de composes de vitamine e au niveau tissulaire et infracellulaire - Google Patents

Administration amelioree de composes de vitamine e au niveau tissulaire et infracellulaire Download PDF

Info

Publication number
CA2366884A1
CA2366884A1 CA002366884A CA2366884A CA2366884A1 CA 2366884 A1 CA2366884 A1 CA 2366884A1 CA 002366884 A CA002366884 A CA 002366884A CA 2366884 A CA2366884 A CA 2366884A CA 2366884 A1 CA2366884 A1 CA 2366884A1
Authority
CA
Canada
Prior art keywords
tocopherol
tris
vitamin
cells
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366884A
Other languages
English (en)
Inventor
Mark Fariss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington State University Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2366884A1 publication Critical patent/CA2366884A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode destinée à améliorer l'apport de composés de vitamine E antioxydants à des tissus, à des cellules et à des sites infracellulaires (aussi bien in vivo qu'in vitro) et, en particulier, aux mitochondries, augmentant ainsi la capacité antioxydante de ces dernières. Les composés de vitamine E administrés peut être clivés par des estérases cellulaires de façon à libérer du .alpha.-T, .beta.-T, .gamma.-T et/ou du .delta.-T antioxydant. L'administration de composés de vitamine E peut en outre avoir une action coordonnée par rapport au traitement des tumeurs en ce que les composés, à l'état intact et non clivé, présentent une activité antitumorale tandis qu'à l'état clivé, ils ont des effets antioxydants.
CA002366884A 1999-04-02 2000-03-31 Administration amelioree de composes de vitamine e au niveau tissulaire et infracellulaire Abandoned CA2366884A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12759399P 1999-04-02 1999-04-02
US60/127,593 1999-04-02
PCT/US2000/008524 WO2000059488A2 (fr) 1999-04-02 2000-03-31 Administration amelioree de composes de vitamine e au niveau tissulaire et infracellulaire

Publications (1)

Publication Number Publication Date
CA2366884A1 true CA2366884A1 (fr) 2000-10-12

Family

ID=22430904

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366884A Abandoned CA2366884A1 (fr) 1999-04-02 2000-03-31 Administration amelioree de composes de vitamine e au niveau tissulaire et infracellulaire

Country Status (4)

Country Link
EP (1) EP1169033A2 (fr)
AU (1) AU4053700A (fr)
CA (1) CA2366884A1 (fr)
WO (1) WO2000059488A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
MX344532B (es) * 2004-10-01 2016-12-19 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
CA2663474C (fr) * 2006-09-15 2017-06-27 Griffith University Composes anti-cancer pro-oxydants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
DE3851842T2 (de) * 1987-10-19 1995-03-02 Liposome Co Inc Wässrige bereitung von liposomenzusammensetzungen.
US5198432A (en) * 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
JPH11335284A (ja) * 1998-05-21 1999-12-07 Isehan:Kk レチノイド類を含有する皮膚外用剤

Also Published As

Publication number Publication date
EP1169033A2 (fr) 2002-01-09
AU4053700A (en) 2000-10-23
WO2000059488A2 (fr) 2000-10-12
WO2000059488A3 (fr) 2001-03-01

Similar Documents

Publication Publication Date Title
da Silva et al. Inhibition of mammalian 15-lipoxygenase-dependent lipid peroxidation in low-density lipoprotein by quercetin and quercetin monoglucosides
Packer Interactions among antioxidants in health and disease: vitamin E and its redox cycle
Upston et al. Tocopherol‐mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement
López-Revuelta et al. Membrane cholesterol contents influence the protective effects of quercetin and rutin in erythrocytes damaged by oxidative stress
Frei On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction
Ciaccio et al. Vitamin A inhibits doxorubicin-induced membrane lipid peroxidation in rat tissues in vivo
Cesquini et al. t-BOOH-induced oxidative damage in sickle red blood cells and the role of flavonoids
Vendemiale et al. An update on the role of free radicals and antioxidant defense in human disease
Sies et al. Cocoa polyphenols and inflammatory mediators
Stahl et al. Antioxidant defense: vitamins E and C and carotenoids
Heinecke Free radical modification of low-density lipoprotein: mechanisms and biological consequences
Villalba et al. Plasma membrane redox system in the control of stress-induced apoptosis
US5198432A (en) Method of preventing chlorohydrocarbon toxicity using sterol derivatives
Coffey et al. In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals.
Thomas et al. Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function.
Fariss et al. Enhanced antioxidant and cytoprotective abilities of vitamin E succinate is associated with a rapid uptake advantage in rat hepatocytes and mitochondria
Lloberas et al. Postischemic renal oxidative stress induces an inflammatory response through PAF and oxidized phospholipids: prevention by antioxidant treatment
Mandal et al. Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis
Palozza et al. Comparative antioxidant activity of tocotrienols and the novel chromanyl-polyisoprenyl molecule FeAox-6 in isolated membranes and intact cells
Pardo-Andreu et al. Mangifera indica L. extract (Vimang®) and its main polyphenol mangiferin prevent mitochondrial oxidative stress in atherosclerosis-prone hypercholesterolemic mouse
Villa et al. Pharmacology of lazaroids and brain energy metabolism: a review
Sepe et al. Oxidant membrane injury by the neutrophil myeloperoxidase system. II. Injury by stimulated neutrophils and protection by lipid-soluble antioxidants.
Brown et al. Effects of vitamin E supplementation on erythrocyte antioxidant defence mechanisms of smoking and non-smoking men
CA2366884A1 (fr) Administration amelioree de composes de vitamine e au niveau tissulaire et infracellulaire
Livrea et al. Antioxidant activity of vitamin A within lipid environments

Legal Events

Date Code Title Description
FZDE Dead